Parkinson's disease (PD) is a common neurological disorder, characterized clinically by progressive disability and pathologically by advancing nigral loss. A variety of dopaminergic therapies, aimed at rectifying the consequences of nigral degeneration, have been developed in the past two decades for symptomatic treatment of PD. Unfortunately, these therapies provide only transient benefit and are attended by a variety of adverse effects. Experimental therapeutics is gradually shifting to preventative strategies aimed at the pathogenesis of PD as we gain a better understanding of the process underlying nigral degeneration. Recent studies in animals and humans implicate toxicity from endogenous and exogenous oxidative mechanisms in the pathogenesis of PD. Preliminary observations from pilot studies suggest that deprenyl, a relatively selective inhibitor of monoamine oxidase type B, and alpha-tocopherol (vitamin E), an antioxidant with free-radical quenching capacities, may ameliorate disability and slow the clinical decline of PD. Our proposal for our clinical trial of deprenyl and tocopherol antioxidative therapies in PD is prompted by the need for preventive therapies, a rationale based on emerging knowledge of pathogenesis, the encouraging results of pilot studies, and the applicability of a feasible design. We hypothesize that chronic deprenyl and/or alpha-tocopherol antioxidative therapies will slow the progressive nigral degeneration and resulting clinical decline of PD. Our preliminary aim is to determine whether or not chronic deprenyl and/or tocopherol administration to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat supervening disability. To this end, we propose a double- blind, multi-institutional, prospective evaluation of PD patients who are in the earliest stages of illness and who are not receiving any symptomatic anti-PD therapies. Subjects will be assigned by randomization using a 2 x 2 factorial design to one of four treatments: 1) deprenyl, 2) tocopherol 3) deprenyl plus tocopherol, or 4) placebo. The primary response variable of interest is the time until levodopa therapy is required to treat disability, up to a maximum of two years of observation. Secondary response variables include clinical and CSF neurochemical measures relevant to the progression of PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS024778-05
Application #
2265362
Study Section
Special Emphasis Panel (SRC (04))
Project Start
1987-04-01
Project End
1995-03-31
Budget Start
1991-04-01
Budget End
1995-03-31
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Rochester
Department
Neurology
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Liu, Ganqiang; Locascio, Joseph J; Corvol, Jean-Christophe et al. (2017) Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol 16:620-629
Liu, Ganqiang; Boot, Brendon; Locascio, Joseph J et al. (2016) Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's. Ann Neurol 80:674-685
DeMarshall, Cassandra A; Han, Min; Nagele, Eric P et al. (2015) Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. Immunol Lett 168:80-8
Pankratz, Nathan; Beecham, Gary W; DeStefano, Anita L et al. (2012) Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol 71:370-84
Marras, Connie; McDermott, Michael P; Marek, Ken et al. (2011) Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord 26:608-13
Evatt, Marian L; DeLong, Mahlon R; Kumari, Meena et al. (2011) High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 68:314-9
Shoulson, Ira (2010) Therapeutic directions for Parkinson's disease. Mov Disord 25 Suppl 1:S152-4
Ascherio, Alberto; LeWitt, Peter A; Xu, Kui et al. (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66:1460-8
Marras, Connie; Lang, Anthony E; Eberly, Shirley W et al. (2009) A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord 24:2370-8
Marras, Connie; McDermott, Michael P; Rochon, Paula A et al. (2008) Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord 23:653-9;quiz 776

Showing the most recent 10 out of 46 publications